Impax loratadine approval
This article was originally published in The Tan Sheet
Executive Summary
Hayward, Calif.-based firm's ANDA for loratadine/pseudoephedrine sulfate 10 mg/240 mg (equivalent to Schering-Plough's Claritin D-24) was approved by FDA, Impax announces March 5. The firm already is authorized to manufacture equivalents to Claritin D-12 and the orally disintegrating Claritin Reditabs. Impax will supply the D-24 equivalent to Wyeth Consumer Healthcare for marketing, mostly likely under the Alavert brand. Wyeth has announced plans for a "complete range" of loratadine products in the Alavert line (1"The Tan Sheet" July 28, 2003, p. 11)...
You may also be interested in...
Alavert Sales Up 48% As Wyeth Stands Strong In Crowded Loratadine Market
Wyeth is confident that its Alavert loratadine product will weather the launch of several private label and generic rivals and build on the brand's strong second quarter sales performance
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.